Butorphanol for treatment of intractable pruritus

Journal of the American Academy of Dermatology

Volumn 54, Issue 3, 2006, Pages 527-531

  Dawn, Aerlyn G ^a   Yosipovitch, Gil ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIHISTAMINIC AGENT; BUTORPHANOL; CLOBETASOL; CORTICOSTEROID; DAPSONE; DESLORATADINE; DIPHENHYDRAMINE; HYDROCORTISONE; HYDROXYZINE; KAPPA OPIATE RECEPTOR AGONIST; LANOLIN ALCOHOL; MIRTAZAPINE; MOMETASONE FUROATE; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; PRAMOCAINE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; ATROPHY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CRYOTHERAPY; DISEASE SEVERITY; DROWSINESS; FEMALE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; SKIN INFLAMMATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BUTORPHANOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; PRURITUS;

EID: 32644464871     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.12.010     Document Type: Article

References (28)

1. G. Yosipovitch, and M.W. Greaves Definitions of itch G. Yosipovitch M.W. Greaves A.B. Fleischer F. McGlone Itch: basic mechanisms and therapy 2004 Marcel Dekker New York 2
2. G. Yosipovitch, A. Goon, J. Wee, Y.H. Chan, and C.L. Goh The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis Br J Dermatol 143 2000 969 973
3. G. Yosipovitch, A.T. Goon, J. Wee, Y.H. Chan, I. Zucker, and C.L. Goh Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus Int J Dermatol 41 2002 212 216
4. G. Yosipovitch, N. Ansari, A. Goon, Y.H. Chan, and C.L. Goh Clinical characteristics of pruritus in chronic idiopathic urticaria Br J Dermatol 147 2002 32 36
5. G. Yosipovitch, M.W. Greaves, and M. Schmelz Itch Lancet 361 2003 690 694
6. Z.Z. Pan mu-Opposing actions of the kappa-opioid receptor Trends Pharmacol Sci 19 1998 94 98
7. H. Umeuchi, Y. Togashi, T. Honda, K. Nakao, K. Okano, and T. Tanaka Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system Eur J Pharmacol 477 2003 29 35
8. N.V. Bergasa An approach to the management of the pruritus of cholestasis Clin Liver Dis 8 2004 55 66
9. Kumagai H, Maruyama S, Gejyo F, Ebata T, Takamori K. Role of mu-and kappa-opioid systems in systemic and peripheral itch, and effects of a novel kappa-agonist, TRK-820 [abstract]. Presented at: Second International Workshop for the Study of Itch. October 23-5, 2003. Toyoma, Japan.
10. Y. Togashi, H. Umeuchi, K. Okano, N. Ando, Y. Yoshizawa, and T. Honda Antipruritic activity of the kappa-opioid receptor agonist, TRK-820 Eur J Pharmacol 435 2002 259 264
11. A.G. Bailey, R.D. Valley, E.B. Freid, and P. Calhoun Epidural morphine combined with epidural or intravenous butorphanol for postoperative analgesia in pediatric patients Anesth Analg 79 1994 340 344
12. J.B. Gunter, J. McAuliffe, T. Gregg, N. Weidner, A.M. Varughese, and D.M. Sweeney Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children Paediatr Anaesth 10 2000 167 172
13. E. Dunteman, M. Karanikolas, and K.S. Filos Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines J Pain Symptom Manage 12 1996 255 260
14. J.E. Bernstein, and R. Swift Relief of intractable pruritus with naloxone Arch Dermatol 115 1979 1366 1367
15. G. Peer, S. Kivity, O. Agami, E. Fireman, D. Silverberg, and M. Blum Randomized crossover trial of naltrexone in uremic pruritus Lancet 348 1996 1552 1554
16. F.H. Wolfhagen, E. Sternieri, W.C. Hop, G. Vitale, M. Bertolotti, and H.R. Van Buuren Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study Gastroenterology 113 1997 1264 1269
17. R. Terg, E. Coronel, J. Sorda, A.E. Munoz, and J. Findor Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study J Hepatol 37 2002 717 722
18. N.V. Bergasa, T.L. Talbot, D.W. Alling, J.M. Schmitt, E.C. Walker, and B.L. Baker A controlled trial of naloxone infusions for the pruritus of chronic cholestasis Gastroenterology 102 1992 544 549
19. N.V. Bergasa, D.W. Alling, T.L. Talbot, M.G. Swain, C. Yurdaydin, and M.L. Turner Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial Ann Intern Med 123 1995 161 167
20. D. Metze, S. Reimann, S. Beissert, and T. Luger Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases J Am Acad Dermatol 41 1999 533 539
21. N. Rawal, U. Schott, B. Dahlstrom, C.E. Inturrisi, B. Tandon, and U. Sjostrand Influence of naloxone infusion on analgesia and respiratory depression following epidural morphine Anesthesiology 64 1986 194 201
22. K.L. Preston, G.E. Bigelow, and I.A. Liebson Butorphanol-precipitated withdrawal in opioid-dependent human volunteers J Pharmacol Exp Ther 246 1988 441 448
23. Mosby's drug consult 2005 Mosby Inc St Louis
24. J.P. Zacny, J.L. Lichtor, J.M. Klafta, R. Alessi, and J.L. Apfelbaum The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers Anesth Analg 82 1996 931 935
25. M. Dershwitz, C.E. Rosow, P.M. DiBiase, and A. Zaslavsky Comparison of the sedative effects of butorphanol and midazolam Anesthesiology 74 1991 717 724
26. M.K. Greenwald, and M.L. Stitzer Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine Drug Alcohol Depend 53 1998 17 30
27. M.D. Ford, K.A. Delaney, L.J. Ling, and T. Erickson Clinical toxicology 2001 WB Saunders Philadelphia p. 628
28. C.S. Koblenzer Psychologic and psychiatric aspects of itching J.D. Bernhard Itch: mechanisms and management of pruritus 1994 McGraw-Hill New York 347 365